Y. Godinov
Janssen (Belgium)(BE)
Publications by Year
Research Areas
Treatment of Major Depression, Neurotransmitter Receptor Influence on Behavior, Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes, Schizophrenia research and treatment, Olfactory and Sensory Function Studies
Most-Cited Works
- → Esketamine Nasal Spray Improves Rate and Time to Remission Versus Quetiapine Extended Release in Subgroups of Patients With Treatment Resistant Depression and Two or Three Plus Prior Treatment Failures: Results From ESCAPE-TRD, a Randomised Phase IIIb Trial(2023)2 cited
- → Remission/response with esketamine nasal spray versus quetiapine extended release in treatment resistant depression using the Patient Health Questionnaire(2023)1 cited
- → Duration and impact of adverse events with esketamine nasal spray and quetiapine extended release in the ESCAPE-TRD phase IIIb trial(2023)
- → Outcomes with esketamine nasal spray in patients with or without earlier partial or full response: post hoc analyses of ESCAPE TRD(2025)
- → Esketamine nasal spray shows higher remission and response rates over 32 weeks of treatment compared with quetiapine extended-release in patients with treatment resistant depression: Results from ESCAPE-TRD, a randomised, phase IIIb clinical trial(2023)
- → Key considerations on treatment duration: expert consensus recommendations using the Delphi method on esketamine nasal spray for treatment-resistant depression(2024)
- → Study design of ESCAPE-TRD, a long-term, comparative, randomised phase IIIb clinical trial of esketamine nasal spray in treatment resistant depression(2022)
- → Treatment patterns of esketamine nasal spray amongst patients with treatment resistant depression in a phase IIIb study: results from ESCAPE-TRD(2024)
- → Top-line Results from ESCAPE-LTE: An Open-Label Extension Study to Assess Long-term Safety of Esketamine Nasal Spray in Treatment Resistant Depression(2025)
- → Disease-specific quality of life with esketamine nasal spray versus quetiapine extended release in treatment resistant depression: results from ESCAPE-TRD(2024)